Myasthenia and the neuromuscular junction

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 523-529

  Gilhus, Nils E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

congenital myasthenic syndromes; Lambert Eaton myasthenic syndrome; myasthenia gravis; myasthenic syndromes; neuromuscular transmission; thymus

Indexed keywords

3,4 DIAMINOPYRIDINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MUSCLE SPECIFIC KINASE; POSTSYNAPTIC LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; TRANSCRIPTION FACTOR SOX; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CHOLINERGIC RECEPTOR MYASTHENIA GRAVIS; CONGENITAL MYASTHENIC SYNDROME; HEART DISEASE; HUMAN; MUSCLE BIOPSY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PLASMAPHERESIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THYMECTOMY; THYMOMA;

ANIMALS; AUTOANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PLASMA EXCHANGE; THYMECTOMY; THYMUS GLAND;

EID: 84866332959     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283572588     Document Type: Review

References (61)

1. Barisic N, Chaouch A, Mü ller JS, et al. Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. Eur J Pediatr Neurol 2011; 15:189-196.
2. Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis; a nationwide epidemiologic study. Neurology 2009; 73:150-151.
3. Andersen JB, Engeland A, Owe JF, et al. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010; 17:1445-1450.
4. Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011; 76:1526-1528.
5. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndromeand their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250:698-701. (Pubitemid 36718358)
6. Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis diagnosis and therapy. Autoimmune Dis 2011. doi10:4061/2011/973808:5p. [Epub ahead of print]
7. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131:1940-1952. (Pubitemid 351957451)
8. Yang L, Maxwell S, Leite MI, et al. Nonradioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci 2011; 301:71-76.
9. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis; clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44:36-40.
10. Suhail H, Subbiah V, Singh S, et al. Serological and clinical features of patients with myasthenia gravis in North Indian population. Int J Neurosci 2010; 120:115-119.
11. Ghazanfari N, Fernandez KJ, Murata Y, et al. Muscle specific kinase; organiser of synaptic membrane domains. Int J Biochem Cell Biol 2011; 43:295-298.
12. Cole RN, Ghazanfari N, Ngo ST, et al. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to dissembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010; 17:3217-3229.
13. Farrugia ME, Bonifati DM, Clover L, et al. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 2007; 185:136-144. (Pubitemid 46497437)
14. Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77:1819-1828.
15. Mori S, Kubo S, Akiyoshi T, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012; 180:798-810.
16. Punga AR, Maj M, Lin S, et al. MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur J Neurosci 2011; 33: 890-898.
17. Cenacchi G, Valentina P, Marina F, et al. Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies. J Neurol 2011; 258:746-752.
18. Higuchi O, Hamuo J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69:418-422.
19. Suzuki S, Satoh T, Yasuoko H, et al. Novel autoantibodies to a voltagegated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 2005; 170:141-149. (Pubitemid 41740915)
20. Romi F, Suzuki S, Suzuki N, et al. Antivoltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012; 259:1312-1316.
21. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis; reactivity and possible clinical significance. Arch Neurol 2005; 62:442-446. (Pubitemid 40349480)
22. Urbano FJ, Pagani MR, Uchitel O. Calcium channels, neuromuscular synaptic transmission and neurological diseases. J Neuroimmunol 2008; 201-202: 136-144.
23. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29:902-908.
24. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome; frequency and relation with survival. J Clin Oncol 2009; 27:4260-4267.
25. Selman MHJ, Niks EH, Titulaer MJ, et al. IgG Fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 2011; 10:143-152.
26. Helgeland G, Petzold A, Luckman SP, et al. Matrix metalloproteinases in myasthenia gravis. Eur Neurol 2011; 65:53-58.
27. Helgeland G, Petzold A, Hoff JM, et al. Antiheat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome. J Neuroimmunol 2010; 22:180-183.
28. Romi F, Helgeland G, Gilhus NE. Heat-shock proteins in clinical neurology. Eur Neurol 2011; 66:65-69.
29. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009; 66:1334-1338.
30. Liewluck T. Immune-mediated rippling muscle disease; another inflammatory myopathy in myasthenia gravis. Arch Neurol 2010; 67:896-897.
31. Aarli JA. Herzmyasthenie; myasthenia of the heart. Arch Neurol 2009; 66:1322-1323.
32. Antevil JL, Carroll CG, Roberts PF, et al. Myasthenia gravis; an unexpected cause of respiratory failure and reversible left ventricular dysfunction after cardiac surgery. J Cardiac Surg 2010; 25:662-664.
33. Mandawat A, Mandawat A, Kaminski HJ, et al. Outcome of plasmapheresis in myasthenia gravis; delayed therapy is not favorable. Muscle Nerve 2011; 43:578-584.
34. Peric S, Rakocevic-Stojanovic V, Nisic T, et al. Cardiac autonomic control in patients with myasthenia gravis and thymoma. J Neurol Sci 2011; 307:30-33.
35. Owe JF, Davidsen ES, Eide GE, et al. Left ventricular long-axis function in myasthenia gravis. J Neurol 2008; 255:1777-1784.
36. Cavalcante P, Panse RL, Berrih-Aknin S, et al. The thymus in myasthenia gravis; site of 'innate autoimmunity'? Muscle Nerve 2011; 44:467-484.
37. Kisand K, Lilic D, Casanova J-L, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients; clinical and pathogenetic implications. Eur J Immunol 2011; 41:1517-1527.
38. Hapnes L, Willcox N, Oftedal B, et al. Radioligand binding assay reveals distinct autoantibody preferences for type I interferons in APS 1 and myasthenia gravis subgroups. J Clin Immunol 2012; 32:230-237.
39. Aricha R, Feferman T, Scott HS, et al. The susceptibility of Aire-/-mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 2011; 36:16-24.
40. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67:726-738.
41. Meyer M, Hö ls A-K, Liersch B, et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011; 70:515-518.
42. Kakalacheva K, Maurer MA, Tackenberg B, et al. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011; 70:508-514.
43. Serafini B, Cavalcante P, Bernasconi P, et al. Epstein-Barr virus in myasthenia gravis thymus; a matter of debate. Ann Neurol 2011; 70:519.
44. Ramanujam R, Piehl F, Pirskanen R, et al. Concomitant autoimmunity in myasthenia gravis; lack of association with IgA deficiency. J Neuroimmunol 2011; 236:118-122.
45. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893-902.
46. Gilhus NE, Owe JF, Hoff JM, et al. Myasthenia gravis; a review of available treatment approaches. Autoimmune Dis 2011. doi: 10.4061/2011/847393. [Epub ahead of print]
47. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiat 2006; 77:203-207. (Pubitemid 43220844)
48. Pouwels S, Javaid M, de Boer A, et al. Risk of fracture in patients with myasthenia gravis; the general practice research database [abstract]. Bone 2011; 48 (suppl. 2):S270.
49. Benveniste O, Hilton-Jones D. The role of rituximab in the treatment of myasthenia gravis. Eur Neurol Rev 2010; 5:95-100.
50. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82:671-673.
51. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82:659-663.
52. Yoshikawa H, Kiuchi T, Saida T, et al. Randomised, double-blind, placebocontrolled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82:970-977.
53. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71:400-406.
54. The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394-399.
55. Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibodypositive myasthenia gravis; outcomes in 102 patients. Muscle Nerve 2010; 41:593-598.
56. Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11:97.
57. Lashley D, Palace J, Jayawant S, et al. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010; 74: 1517-1523.
58. Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44:789-794.
59. Barth D, Nabavi N, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76:2017-2023.
60. Mandawat A, Kaminski H, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010; 68: 797-805.
61. Gilhus NE. Acute treatment for myasthenia gravis. Nat Rev Neurol 2011; 7:132-134.